- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02993159
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To demonstrate that 2 mg once daily per breast of 4-hydroxytamoxifen (4-OHT) topical gel results in a reduction in the Ki-67 labeling index of ductal breast carcinoma in situ (DCIS) lesions that is not inferior to that seen with 20 mg daily oral tamoxifen citrate (TAM) for 4-10 weeks, when comparing the base-line diagnostic core biopsy to the therapeutic surgical excision sample.
SECONDARY OBJECTIVES:
I. To compare post-therapy changes in the oncotype DCIS-score between arms (this is a validated reverse transcriptase-polymerase chain reaction [RT-PCR] assay for Ki67, STK15, survivin, cyclin B1, MYBL2, PR, GSTM1).
II. To compare between-group post-therapy changes in immunohistochemistry (IHC) markers: CD-68 macrophage marker as a surrogate for response to therapy, p16 and COX-2.
III. To compare post-therapy changes in breast density, quantitative estimate, between arms.
IV. To compare post-therapy breast tissue and plasma levels of TAM and its metabolites (N-desmethyl tamoxifen [NDT], [E] and [Z] isomers of 4-hydroxytamoxifen [4-OHT], N-desmethyl-4-hydroxytamoxifen [endoxifen]).
V. To compare post-therapy breast tissue and plasma levels of estradiol and progesterone between arms (optional).
VI. To compare the post-therapy fraction of participants demonstrating "no residual DCIS".
VII. To compare post-therapy changes in plasma proteins involved in coagulation: factors VIII and IX, von Willebrand factor, total protein S between arms.
VIII. To compare post-therapy changes in plasma markers of systemic estrogenic effect (IGF-1, SHBG).
IX. To compare post-therapy changes in symptoms as captured in the breast cancer prevention trial (BCPT) Eight Symptom Scale (BESS) questionnaire and skin reactions to 4-OHT gel.
OUTLINE: Patients are randomized into 1 of 2 arms.
ARM I: Patients apply afimoxifene gel to both breasts and receive placebo orally (PO) daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
ARM II: Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed up at 1-2 weeks and 1 month after surgery.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Principle Investigator
- Phone Number: 312-503-4236
- Email: skhan@nm.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Seema A. Khan, MD
- Phone Number: 312-503-4236
- Email: skhan@nm.org
-
Principal Investigator:
- Seema A. Khan, MD
-
-
Kentucky
-
Edgewood, Kentucky, United States, 41017
- Recruiting
- Saint Elizabeth Medical Center South
-
Contact:
- Joseph M. Guenther, MD
- Phone Number: 859-344-1600
- Email: Joseph.Guenther@stelizabeth.com
-
Principal Investigator:
- Joseph M. Guenther, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Amy C. Degnim, MD
- Phone Number: 507-284-4499
- Email: degnim.amy@mayo.edu
-
Principal Investigator:
- Amy C. Degnim, MD
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan-Kettering Cancer Center
-
Contact:
- Melissa L. Pilewskie, MD
- Phone Number: 646-888-4590
- Email: pilewskm@mskcc.org
-
Principal Investigator:
- Melissa L. Pilewskie, MD
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Medical Center
-
Contact:
- Eun-Sil (Shelley) Hwang, MD
- Phone Number: 919-684-6849
- Email: shelly.hwang@duke.edu
-
Principal Investigator:
- Eun-Sil (Shelley) Hwang, MD
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Cleveland Clinic
-
Contact:
- Stephen R. Grobmyer, MD
- Phone Number: 216-636-2843
- Email: TaussigResearch@ccf.org
-
Principal Investigator:
- Stephen R. Grobmyer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Screen-detected, estrogen receptor (ER) positive DCIS of the breast proven on core needle biopsy, defined as 10% positive cells; the presence of a focus suspicious for microinvasion will be allowed; the size of the DCIS in the core biopsy sample must total 5 mm (multiple cores can be summed) and must be estimated on the deepest step section (if step sections are taken)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
- Participants must have acceptable organ and marrow function as defined below:
Baseline lab parameters are not standard of care for initiation of tamoxifen therapy; a minimal panel will therefore be appropriate.
- Leukocytes >= 3,000/microliter
- Absolute neutrophil count >= 1,500/microliter
- Platelets >= 100,000/microliter
- Total bilirubin within "≤1.5 x institutional upper limit of normal (ULN)institutional limits
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional upper limit of normal (ULN)
- Creatinine within "≤1.5 x institutional upper limit of normal (ULN) institutional limits
- Women of childbearing potential and their male partners must agree to use TWO effective forms of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for two months following the last dose of study medications; effective birth control methods are: copper IUD [intrauterine device], diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms; women of childbearing potential must have a negative urine pregnancy test within seven days before starting study medications; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
- Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- DCIS presentation as a palpable mass
- Exogenous sex steroid use within 4 weeks prior to core needle biopsy
- Prior ipsilateral breast cancer radiotherapy will be excluded; prior contralateral breast cancer therapy within 2 years will also be excluded
- Skin lesions on the breast that disrupt the stratum corneum (eg eczema, ulceration)
- History of endometrial neoplasia
- History of thromboembolic disease (history of varicose veins and superficial phlebitis is allowed)
- Current smokers
- Current users of potent inhibitors of tamoxifen metabolism must be able to discontinue their use and switch to an alternative medication for the duration of participation, under the advice of their physician; if the physician feels that an alternative medication is not appropriate for the subject and the current medication is medically necessary, the subject will not be eligible; the drugs are listed below; many of these are not in clinical use at the moment; bupropion, celecoxib, chlorpheniramine, chlorpromazine, cimetidine, citalopram, clemastine, clomipramine, clozapine, cocaine, delavirdine, desipramine, diphenhydramine, doxepin, duloxetine, escitalopram, fluoxetine, haloperidol, halofantrine, hydroxyzine, imipramine, isoniazid, ketoconazole, methadone, methimazole, mibefradil, miconazole, nicardipine, paroxetine, pergolide, perphenazine, pioglitazone, pyrimethamine, quinidine, quinine, ranitidine, ritonavir, ropinirole, sertraline, terbinafine, thioridazine, ticlopidine, tranylcypromine, trazodone, tripelennamine
- Prior use of SERMS or AIs including tamoxifen, raloxifene, anastrozole, letrozole, or exemestane for prevention or therapy within 5 years
- Participants may not be receiving any other investigational agents within 30 days of enrollment or during this study
- History of allergic reactions attributed to tamoxifen or compounds of similar chemical or biologic composition
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued by nursing mothers who agree to participate in the study
- Men are excluded from this study since DCIS of the breast is exceedingly rare in men, and there are no data regarding skin penetration of 4-OHT though male chest wall skin (which is thicker and hairier than female chest wall skin)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (afimoxifene, placebo)
Patients apply afimoxifene gel to both breasts and receive placebo PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
|
Correlative studies
Given PO
Other Names:
Applied to the breast
Other Names:
Applied to the breast
Other Names:
|
Active Comparator: Arm II (placebo, tamoxifen citrate)
Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
|
Correlative studies
Given PO
Other Names:
Given PO
Other Names:
Applied to the breast
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ki67 labeling assessed by standard immunohistochemistry
Time Frame: Up to 1 month after surgery
|
Up to 1 month after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CD68, p16, and COX2 assessed by IHC
Time Frame: Up to 1 month after surgery
|
Analysis will be pilot in nature and will provide descriptive statistics for each group or subgroup of subjects, supplying results which may be used to plan future studies.
|
Up to 1 month after surgery
|
Estradiol and progesterone levels in breast tissue and plasma assessed by liquid chromatography/tandem mass spectrometry
Time Frame: Up to 1 month after surgery
|
Analysis will be pilot in nature and will provide descriptive statistics for each group or subgroup of subjects, supplying results which may be used to plan future studies.
|
Up to 1 month after surgery
|
Fraction of subjects with "no residual DCIS" in surgical sample assessed by core needle biopsy
Time Frame: Up to 1 month after surgery
|
Analysis will be pilot in nature and will provide descriptive statistics for each group or subgroup of subjects, supplying results which may be used to plan future studies.
|
Up to 1 month after surgery
|
Oncotype DCIS-score assessed by RT-PCR
Time Frame: Up to 1 month after surgery
|
Analysis will be pilot in nature and will provide descriptive statistics for each group or subgroup of subjects, supplying results which may be used to plan future studies.
|
Up to 1 month after surgery
|
Pathologic complete response defined as absence of residual DCIS or residual DCIS responded completely to therapy
Time Frame: Up to 1 month after surgery
|
Up to 1 month after surgery
|
|
Plasma markers of systemic estrogenic effect (IGF-1, SHBG)
Time Frame: Up to 1 month after surgery
|
Analysis will be pilot in nature and will provide descriptive statistics for each group or subgroup of subjects, supplying results which may be used to plan future studies.
|
Up to 1 month after surgery
|
Plasma proteins involved in coagulation (factors VIII and IX, von Willebrand factor, and total protein S)
Time Frame: Up to 1 month after surgery
|
Analysis will be pilot in nature and will provide descriptive statistics for each group or subgroup of subjects, supplying results which may be used to plan future studies.
|
Up to 1 month after surgery
|
Symptoms assessed by BESS questionnaire
Time Frame: Up to 1 month after surgery
|
Will evaluate hot flashes, vaginal discharge/dryness, skin reactions to afimoxifene gel.
Analysis will be pilot in nature and will provide descriptive statistics for each group or subgroup of subjects, supplying results which may be used to plan future studies.
|
Up to 1 month after surgery
|
TAM and its metabolites levels in breast tissue and plasma
Time Frame: Up to 1 month after surgery
|
Analysis will be pilot in nature and will provide descriptive statistics for each group or subgroup of subjects, supplying results which may be used to plan future studies.
|
Up to 1 month after surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma, Ductal
- Carcinoma in Situ
- Breast Neoplasms
- Carcinoma
- Breast Carcinoma In Situ
- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Ductal, Breast
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Bone Density Conservation Agents
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Tamoxifen
- Afimoxifene
Other Study ID Numbers
- NCI 2015-06-04 (Other Identifier: Northwestern University)
- P30CA060553 (U.S. NIH Grant/Contract)
- N01-CN-2012-00035
- N01CN00035 (U.S. NIH Grant/Contract)
- NCI-2016-01911 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- NWU2015-06-04 (Other Identifier: DCP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Estrogen Receptor Positive
-
National Cancer Institute (NCI)TerminatedStage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor PositiveUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...TerminatedEstrogen Receptor Positive Breast Cancer | Androgen Receptor Gene Overexpression | Progesterone Receptor Positive Tumor | Metastatic Breastcancer | Estrogen Receptor Negative Neoplasm | Progesterone Receptor Negative NeoplasmItaly
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaboratorsTerminatedStage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Merck Sharp & Dohme LLCCompletedStage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast CarcinomaUnited States
-
Eisai Inc.CompletedBreast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast CancerFrance, United Kingdom, United States
-
Syndax PharmaceuticalsCompletedBreast Cancer | ER+ Breast Cancer | Estrogen Receptor-Positive Breast Cancer | Breast Cancer, Estrogen Receptor-PositiveUnited States, Czechia, Canada, Hungary, Russian Federation
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7United States, Puerto Rico
-
AC Camargo Cancer CenterH. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingNeuroendocrine Tumors | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive TumorUnited States, Brazil
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingInvasive Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor PositiveUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States